@article{0695235ad30a4f5dac0c4c215172f3ed,
title = "The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158",
author = "Mistry, \{Pramod K.\} and Kishnani, \{Priya S.\} and Manisha Balwani and Charrow, \{Joel M.\} and Judy Hull and Weinreb, \{Neal J.\} and Cox, \{Timothy M.\}",
note = "Funding Information: Medical writing/editorial support for this article was paid for by Sanofi. Funding Information: P.K.M., P.S.K., M.B., J.M.C., N.J.W. and T.M.C. are principal investigators in Sanofi-sponsored clinical trials and/or members of regional advisory boards of the Sanofi-sponsored International Collaborative Gaucher Group Gaucher Registry, and have received research funding, educational grants, honoraria, consulting fees, and/or travel reimbursement from Sanofi. P.S.K. also reports serving on advisory boards for Amicus and Baebies; consulting fees from Amicus, AskBio, and Vertex; contracted research for Amicus and Valerion; honoraria from Amicus, AskBio, and Vertex; travel expenses from Amicus; and ownership interests in AskBio and Baebies. M.B. also reports participation on advisory boards for Takeda. N.J.W. also reports honoraria for consultancy or participation on advisory boards for Pfizer and Shire and fees or honoraria from speaking at the invitation of Pfizer and Shire. T.M.C. also reports consulting fees from AvroBio, Azafaros, Gain Therapeutics, Pfizer, and Takeda, and honoraria, travel reimbursement, and grant/research support from Shire Pharmaceuticals (now Takeda). J.H. is employed by Sanofi. ",
year = "2023",
month = may,
doi = "10.3390/jcm12093269",
language = "English",
volume = "12",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",
}